Leveraging Resources of Partners to Optimize Value Creation and Capture

Arthur A. Boni, Ph. D.

"Open Innovation 101" Capital Efficient Business Models to Accelerate Innovation



Reference

 Arthur A. Boni and Christopher Moehle – "Biotechnology Lessons for Robotics: Adapting New Business Models to Accelerate Innovation"J. Commercial Biotechnology, Vol. 20, pp. 37-44 (2014)

Background on Ol Bio 2019 Bio 2019 the pace of innovation is challenged

Promoted by Henry Chesbrough

- Exec Director of Open Innovation Institute at U. California, Berkeley (formerly at Harvard)
- New markets for knowledge driven by:
 - Increasing availability and knowledge of smart, creative workers worldwide
 - External options for ideas "on the shelf" or available (including crowdsourcing)
 - Global expansion of IT networks for global connect on a 24/7 basis
 - Growth and maturation of the VC market locally and globally
 - Increasing capacity and appetite of external partners for ideas
 - Capital inefficiency of "vertical integration"

© Arthur A.

Open Innovation Facts

© Arthur A. Boni, Ph. D. BIO 2019


 Boundaries between firm and environment are now permeable

- Vertical integration (or owning the entire value chain) is "disrupted"
- Partner for access to resources not controlled by the firm
- Expand ideas & paths to market
 knowledge is distributed widely,
 so buy or license it
- Some ideas cannot or should not, be pursued by the firm directly, so spin them off
 - Christensen's Innovators Dilemma and Solution

- Short list of who is using it:
 - IBM, Intel, GE, Phillips, Google, Apple, Amazon, Siemens
 - Salesforce, UnderArmour, 3M, Kraft, P&G
 - Eli Lilly/Innocentive, J&J, GSK
- 79% draw on innovations from outside their industry! (Nine Sigma & Harris Interactive)


Open source and open innovation are complements

- Shared software
- Projects or communities act as innovation intermediaries



What parts should you rent? Boni, Ph. D. BIO 2019


6



Ref. Osterwalder

Minimize risk and capital to optimize value and build brand

- The Business Model contains all elements required by a firm to create, deliver and capture value.
- In developing and validating the business model elements, the firm can leverage the resources and channels of partners across the value chain, and share the value created and delivered with others.
 - Partner selectively and appropriately, e. g. clinical testing (CRO or pharma?); manufacturing (CMO?), channel access (pharma?),
 - Extreme version is "a virtual company", at least thru the early stages



DNA for Collaborative Innovation

An open innovation ecosystem (from Chesbrough)

- Collaborative networks "outside in" and "inside out"
- Private/public partnerships

Cross-disciplinary, diverse, collaborative teams working across the product life cycle (from Pisano; Boni et al)

- Organizational structures to "translate research and technology from laboratory to market" efficiently
- Technology, Business, Design, + ---

Culture built around 5 behavioral traits: "base pairs" (from Christensen et al)

 Questioning, Observing, Experimenting, Networking + Associative Thinking (connecting the dots)

Three Fundamental Lessons


- 1. Focus on creative value sharing
- 2. Create stage-appropriate financing vehicles (to cross "valley of death")
- **3.** Develop and grow "seasoned" management teams through collaborations, accelerators, etc.

Lesson 1: Focus on Creative Value Sharing – the Collaborative Team



Leverage academia, emerging companies, and industry to form extended teams across the value chain.

Ex 1: Eli Lilly's FIP Net Model Spans the Biopharma 11 Value Chain and Globe



Ex. 2: Enlight Bioscience Bio 2019 Created by Pure Tech Ventures




A consortium leveraging selected market driven opportunities

Lesson 2: Create "Stage Appropriate" Financing Vehicles

- Create "stage appropriate" financing vehicles for "crossing valley of death" from laboratory to clinic to patient
 - Third Rock Ventures ab initio formation and growth of Foundation Medicine using open innovation principles learned at Millennium Pharmaceuticals
 - The Harrington Project/BioMotiv
- Partnerships, staged financing, team building from experienced industry "veterans"

Ex 1: Third Rock Ventures




Discover

Launch

Build

Foundation Medicine – leadership in personalized medicine

Ex. 2 - Harrington/BioMotiv



© Arthur A.

Boni, Ph. D. BIO 2019

Lesson 3: Grow "Seasoned" BIO 2019 Management Teams



Leverage Collaborations and Accelerators

© Arthur A.

Accelerators in Bioparma are Evolving Jlabs, QB3, Rock Health, etc.

citreix StartupAccelerator



An example from enterprise software

Two Specific Best Practices


Long development cycles and "high risk" suggest a portfolio-based approach

While technology is a driver, need to instill market focus very early in the process – use the "lean startup methodology"


Portfolio Based Approach

Open Innovation -

collaborative development across innovation ecosystem



Instill Early Market Focus ^{© Arthur A.} Boni, Ph. D. BIO 2019 (with all P's in biopharma and medtech)



20

Build an OI Culture into your Business Model

© Arthur A. Boni, Ph. D.

BIO 2019

<u>"Defer to Open"</u>

- Innovation comes from anywhere in the organization
- Be receptive & seek ideas from the outside
- Be prepared to spin off "opportunities" that don't fit current business model

Operate Lean

- Keep cost of capital low while addressing product/market fit iteratively
- Leverage partnerships across the value chain!

Creative Financing

- Use for-profit and not-for profit sources and partnerships
- Milestone funding for potential new ventures
- Create and Grow Innovation Teams
 - Collaborative interdisciplinary teams evolve thru commercialization and growth phases
 - Access expertise via extended networks

21